Research group - Olle Ringdén

Denna sida på svenska

The group focuses on Clinical and experimental research regarding allogeneic hematopoietic stem cell transplantation.

Main problems are graft-versus-host disease, infections and leukemic relapse. We are aiming to shorten the neutropenic phase by intraarterial infusion of the stem cells. We are using the immunomodulating effects of decidua stroma cells from placentas to reduce the graft-versus-host reaction and toxicity. Furthermore, we are performing studies to improve the clinical results.

  1. Develop optimal protocols for treatment of acute GVHD.
    • Optimal dosing and timing of decidua stroma cells. We evaluate the mechanism behind the immunosuppressive effect of decidua stromal cells. We test if gene manipulated stromal cells can improve immunosuppression in vitro and in vivo. We study the effect of various immunosuppressive drugs and the effects of acetylcystein and interferon-gamma.
    • We study the effect of stromal cells and the role of the thymus and the spleen and interaction with monocytes and macrophages.
    • We do clinical pilot studies of decidua stromal cells for acute GVH.
  2. Together with Professor Staffan Holmin, we will investigate in intraarterial infusion can improve engraftment and decrease leukemic relapse.
  3. Several clinical studies to improve the allogeneic graft-versus-cancer effect are performed. Such studies are performed at Center for Allogeneic Stem Cell Transplantation at Karolinska Institutet in collaboration with Jonas Mattsson.

We perform randomized studies in the Nordic Bone Marrow Transplantation Group. Retrospective multicenter studies are performed within the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation in collaboration with Professor Mohamad Mohty and Dr. Myriam Labopin. We also do studies in collaboration with Center for International Blood and Marrow Transplant Research, Prof. Mary Horowitz and co-workers in Milwaukee, USA.

The studies are performed in collaboration with CAST, Jonas Mattsson etc, Nordiska Benmärgstransplantationsgruppen, Europeiska Benmärgstransplantationsgruppen and Center for International Blood and Marrow Transplant Research.

Research group leader Olle Ringdén

Professor emeritus

Olle Ringden

Organizational unit: TIM

Group members

Behnam SadeghiAssistant professor
Bita KhoeinLaboratory technician
Gianluca MorettiR&D trainee
Gunilla TillingerAssociated
Helen KaipeSenior researcher
Lisbeth BarkholtPostdoc
Martin SoldersPhD student
Mehmet UzunelSenior researcher
Olle RingdenProfessor emeritus
Petter SvenbergGraduate Student
Richard OlssonAssociated
Silvia NavaResearch technician

Research techniques

  • Realtime-PCR
  • genotyping
  • flow cytometry
  • immuno-histochemistry
  • immuno-cytochemistry
  • cell isolation techniques

External funding

Cancerfonden, Barncancerfonden, Swedish Research Council, Karolinska Institutet, The Cancer Society in Stockholm

Teaching assignments

Teaching regarding allogeneic hematopoietic stem cell transplantation for medical students and PhD students.

Selected publications

N-acetyl-L-cysteine increases acute graft-versus-host disease and promotes T-cell-mediated immunity in vitro.
Karlsson H, Nava S, Remberger M, Hassan Z, Hassan M, Ringdén O
Eur. J. Immunol. 2011 Apr;41(4):1143-53

Improved survival after allogeneic hematopoietic stem cell transplantation in recent years. A single-center study.
Remberger M, Ackefors M, Berglund S, Blennow O, Dahllöf G, Dlugosz A, et al
Biol. Blood Marrow Transplant. 2011 Nov;17(11):1688-97

Stromal cells from term fetal membrane are highly suppressive in allogeneic settings in vitro.
Karlsson H, Erkers T, Nava S, Ruhm S, Westgren M, Ringdén O
Clin. Exp. Immunol. 2012 Mar;167(3):543-55

Many days at home during neutropenia after allogeneic hematopoietic stem cell transplantation correlates with low incidence of acute graft-versus-host disease.
Ringdén O, Remberger M, Holmberg K, Edeskog C, Wikström M, Eriksson B, et al
Biol. Blood Marrow Transplant. 2013 Feb;19(2):314-20

Fetal membrane cells for treatment of steroid-refractory acute graft-versus-host disease.
Ringdén O, Erkers T, Nava S, Uzunel M, Iwarsson E, Conrad R, et al
Stem Cells 2013 Mar;31(3):592-601

ImmunologyStem cellsTransplantation